These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 19037041)

  • 1. Discontinuation rates of anticholinergic medications used for the treatment of lower urinary tract symptoms.
    Gopal M; Haynes K; Bellamy SL; Arya LA
    Obstet Gynecol; 2008 Dec; 112(6):1311-1318. PubMed ID: 19037041
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discontinuation of treatment using anticholinergic medications in patients with urinary incontinence.
    Kalder M; Pantazis K; Dinas K; Albert US; Heilmaier C; Kostev K
    Obstet Gynecol; 2014 Oct; 124(4):794-800. PubMed ID: 25198276
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Which anticholinergic drug for overactive bladder symptoms in adults.
    Madhuvrata P; Cody JD; Ellis G; Herbison GP; Hay-Smith EJ
    Cochrane Database Syst Rev; 2012 Jan; 1():CD005429. PubMed ID: 22258963
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness and tolerability of extended-release oxybutynin vs extended-release tolterodine in women with or without prior anticholinergic treatment for overactive bladder.
    Anderson RU; MacDiarmid S; Kell S; Barada JH; Serels S; Goldberg RP
    Int Urogynecol J Pelvic Floor Dysfunct; 2006 Sep; 17(5):502-11. PubMed ID: 16724169
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anticholinergic medication use for female overactive bladder in the ambulatory setting in the United States.
    Ju R; Garrett J; Wu JM
    Int Urogynecol J; 2014 Apr; 25(4):479-84. PubMed ID: 24158462
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Persistence and Adherence with Mirabegron versus Antimuscarinic Agents in Patients with Overactive Bladder: A Retrospective Observational Study in UK Clinical Practice.
    Chapple CR; Nazir J; Hakimi Z; Bowditch S; Fatoye F; Guelfucci F; Khemiri A; Siddiqui E; Wagg A
    Eur Urol; 2017 Sep; 72(3):389-399. PubMed ID: 28196724
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparing anticholinergic persistence and adherence profiles in overactive bladder patients based on gender, obesity, and major anticholinergic agents.
    Lua LL; Pathak P; Dandolu V
    Neurourol Urodyn; 2017 Nov; 36(8):2123-2131. PubMed ID: 28467609
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term patterns of use and treatment failure with anticholinergic agents for overactive bladder.
    Chancellor MB; Migliaccio-Walle K; Bramley TJ; Chaudhari SL; Corbell C; Globe D
    Clin Ther; 2013 Nov; 35(11):1744-51. PubMed ID: 24091072
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Which anticholinergic drug for overactive bladder symptoms in adults.
    Hay-Smith J; Herbison P; Ellis G; Morris A
    Cochrane Database Syst Rev; 2005 Jul; (3):CD005429. PubMed ID: 16034974
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatments for overactive bladder: focus on pharmacotherapy.
    Geoffrion R;
    J Obstet Gynaecol Can; 2012 Nov; 34(11):1092-1101. PubMed ID: 23231848
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adherence, persistence and switch rates for anticholinergic drugs used for overactive bladder in women: data from the Norwegian Prescription Database.
    Mauseth SA; Skurtveit S; Spigset O
    Acta Obstet Gynecol Scand; 2013 Oct; 92(10):1208-15. PubMed ID: 23763552
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association between cumulative anticholinergic burden and falls and fractures in patients with overactive bladder: US-based retrospective cohort study.
    Szabo SM; Gooch K; Schermer C; Walker D; Lozano-Ortega G; Rogula B; Deighton A; Vonesh E; Campbell N
    BMJ Open; 2019 May; 9(5):e026391. PubMed ID: 31061036
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Persistence with first line anticholinergic medication in treatment-naïve overactive bladder patients.
    Krhut J; Gärtner M; Petzel M; Sykora R; Nemec D; Tvrdik J; Skoupa J
    Scand J Urol; 2014 Feb; 48(1):79-83. PubMed ID: 23870042
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Are anticholinergic medications used for overactive bladder associated with new onset depression? A population-based matched cohort study.
    Welk B; McArthur E
    Pharmacoepidemiol Drug Saf; 2020 Dec; 29(12):1710-1714. PubMed ID: 33015899
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Should we switch over to tolterodine in every child with non-neurogenic daytime urinary incontinence in whom oxybutynin failed?
    Yucel S; Akkaya E; Guntekin E; Kukul E; Danisman A; Akman S; Baykara M
    Urology; 2005 Feb; 65(2):369-73. PubMed ID: 15708055
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Overactive bladder in an integrated delivery system: a longitudinal cohort study.
    Linder JA; Weissman JS; Reyes Nieva H; Lipsitz S; Haring RS; DeAngelis J; Kristy RM; Loughlin KR
    BMC Health Serv Res; 2020 May; 20(1):447. PubMed ID: 32434511
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anticholinergic therapy: do the patients take the pills prescribed?
    Jundt K; Schreyer K; Friese K; Peschers U
    Arch Gynecol Obstet; 2011 Sep; 284(3):663-6. PubMed ID: 21046135
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Limitations of anticholinergic cycling in patients with overactive bladder (OAB) with urinary incontinence (UI): results from the CONsequences of Treatment Refractory Overactive bLadder (CONTROL) study.
    Chancellor MB; Yehoshua A; Waweru C; Globe D; Cheng IN; Campbell KL; Joshi M; Pulicharam R
    Int Urol Nephrol; 2016 Jul; 48(7):1029-36. PubMed ID: 27032397
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Differences of urodynamic tests between patients of detrusor hyperactivity with impaired contractility with and without bladder outlet obstruction and effect of anticholinergic medications in these patients].
    Liu N; He F; Man LB; Huang GL; Wang HD; Wang H; Li GZ; Wang JW
    Zhonghua Yi Xue Za Zhi; 2012 Jul; 92(26):1824-7. PubMed ID: 22944232
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Persistence with prescribed antimuscarinic therapy for overactive bladder: a UK experience.
    Wagg A; Compion G; Fahey A; Siddiqui E
    BJU Int; 2012 Dec; 110(11):1767-74. PubMed ID: 22409769
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.